Myopia

Fuensanta A. Vera-Diaz, OD, PhD, FAAO, Director of Research and Associate Professor of Optometry at the New England College of Optometry (NECO) repersented AAO at the first meeting of the Committee on Focus on Myopia.

Johnson & Johnson Vision’s ACUVUE Abiliti brand announces its back-to-school campaign to inform parents about myopia and the growing risk of the disease

Pediatric keratoconus is often more challenging to diagnose, resulting in treatment delay and vision loss.

A recent study found that the use of low-dose atropine drops is ineffective in slowing pediatric myopia progression, contradicting a previous study.

At NOA 2023, Brianna Rhue, OD, FAAO, FSLS, caught up with Optometry Times to tell us more about the now and how of myopia management.

Brianna Rhue, OD, FAAO, FSLS, met with Optometry Times to talk about her presentation titled, "Myopia- How and Now," which she will be sharing at the National Optometric Association in Fort Lauderdale, Florida.

These findings demonstrate the exact association between high myopia and changes in the ocular blood flow, which heretofore had not been established.

At AOA Optometry's Meeting 2023, in Washington, DC, Justin Kwan, OD, FAAO, provides updates on the latest at CooperVision, including new data on MiSight myopia management contact lenses and information on their ortho-K software, Visavy.

Studies suggest that high glycemic load carbohydrate diets may alter the genetic influence of growth of the sclera and choroid, which ultimately can induce permanent changes in the development and progression of myopia.

Kevin Chan, OD, MS, FAAO, gives us an insider look at his AOA 2023 presentation, "Top 5 myths of myopia management and how to overcome them."

Optometrists should be aware of the consequences of digital device use beyond myopia.

NVK002 is a proprietary, investigational, preservative-free eye drop administered nightly and intended for patients ages 3 to 17.

Instrumentation recreates properties of the myopic eye to test lenses that prevent visual decline.

Growing evidence supports dual therapy to slow progression.

An epidemiologic study of myopia in a Chinese province found that economic status, gender, and age were associated with rates of myopia.

Currently, there are several novel spectacle designs available across the world. Unfortunately, none of them are available in the US currently.

Although the use of atropine is not necessarily novel in the myopia management world, the fact that practitioners may soon have an FDA approved formulation of atropine is new and exciting.

New research suggests sleep is an additional risk factor affecting myopia onset and progression.

In a sham device-controlled, randomized, double-blind clinical trial in China, researchers utilized a device that emits 650 nm red light directly to the retina.

The 20-20-20 rule has taken on a life of its own, but it remains a useful trick to reduce digital eye strain.

Andrew Pucker, OD, MS, PhD, FAAO, and George Magrath, MD, discuss Lexitas Pharma Services' work on modification of the National Eye Institute's corneal fluorescein staining scale.

Mark Bullimore, PhD, MCOptom, shares a brief overview of her presentation on myopia management by slowing progression with low concentration atropine.

Positive 42-month Cypress axial length and cSER outcomes, presented at ARVO in New Orleans, reinforce myopia control safety and efficacy of Diffusion Optics Technology™ spectacle lenses.

Although the 20-20-20 rule is still a solid recommendation, recent studies have provided practitioners with more specific recommendations to help potentially prevent the onset and slow the progression of myopia.

The technology will be shared at the International Congress of Ophthalmology and Optometry China (COOC) conference in Shanghai April 14-16, 2023.